Compare BHRB & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHRB | IVA |
|---|---|---|
| Founded | 1852 | 2011 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 907.7M | 769.0M |
| IPO Year | N/A | 2020 |
| Metric | BHRB | IVA |
|---|---|---|
| Price | $66.68 | $4.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $71.67 | $17.14 |
| AVG Volume (30 Days) | 43.9K | ★ 307.1K |
| Earning Date | 01-23-2026 | 09-29-2025 |
| Dividend Yield | ★ 3.30% | N/A |
| EPS Growth | ★ 264.64 | N/A |
| EPS | ★ 7.05 | N/A |
| Revenue | ★ $331,643,000.00 | $19,929,536.00 |
| Revenue This Year | $51.05 | N/A |
| Revenue Next Year | $5.90 | N/A |
| P/E Ratio | $9.45 | ★ N/A |
| Revenue Growth | ★ 82.85 | N/A |
| 52 Week Low | $47.57 | $2.11 |
| 52 Week High | $71.75 | $7.98 |
| Indicator | BHRB | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 67.87 | 45.56 |
| Support Level | $64.07 | $3.98 |
| Resistance Level | $67.75 | $4.25 |
| Average True Range (ATR) | 1.69 | 0.22 |
| MACD | 0.45 | 0.04 |
| Stochastic Oscillator | 86.29 | 29.33 |
Burke & Herbert Financial Services Corp is the bank holding company. Through its subsidiary, it predominantly serves small to medium-sized businesses, their owners and employees, professional corporations, non-profits, and individuals with various banking products and financial services. Some of its products and service offerings include checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential mortgage, acquisition, construction, and development loans, online banking, mobile banking, and wealth and trust services. The company operates in a single segment, namely Community Banking.
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.